The Supplement That Feeds Four Healing Pathways at Once
Ornithine alpha-ketoglutarate (OKG) is a single compound that simultaneously generates collagen precursors, immune fuel, blood vessel growth signals, and cell proliferation triggers — with moderate RCT evidence showing 43% faster wound closure in elderly patients.
vs. Placebo (p=0.007)
in Landmark RCT
Costs (Brocker 1994)
Fed Simultaneously
Every year, millions of people face the slow, frustrating reality of wound healing — whether recovering from surgery, managing pressure ulcers, or rebuilding tissue after a serious injury. What if a single compound could simultaneously support collagen production, immune defence, blood vessel growth, and cell proliferation? That is the premise behind ornithine alpha-ketoglutarate (OKG) — a compound that has been quietly accumulating clinical evidence for over 40 years.
Why Healing Is Harder Than It Looks
Healing is metabolically expensive. After surgery, a burn injury, or even prolonged bed rest, the body’s demand for specific amino acids — particularly arginine, proline, and glutamine — far outstrips what normal food intake can provide. Plasma arginine levels drop by 25–50% after surgery and by up to 80% after major burns. Glutamine, the primary fuel for immune cells and gut lining, becomes conditionally essential under physiological stress.
Pressure ulcers alone affect 10–30% of hospitalised elderly patients, with healing timelines measured in months. In the UK, complex wounds cost the NHS an estimated £5.3 billion annually. For severely burned patients, resting energy expenditure increases by 40–100% and protein losses can reach 20–25% of pre-burn lean mass within three weeks. The wound healing cascade demands arginine for blood vessel formation, proline for collagen deposition, glutamine for immune cell function, and polyamines for the cell proliferation that closes wounds — all at the same time, all in short supply.
The clinical question is not whether nutrition matters for healing — it clearly does. The question is which nutritional interventions have meaningful evidence behind them. Most amino acid supplements address one of these bottlenecks. OKG addresses all four from a single oral supplement.
What Is OKG — and Why Does It Work Differently?
Ornithine alpha-ketoglutarate is a salt made of two amino acid–related molecules: L-ornithine and alpha-ketoglutarate (AKG). It is not a drug — it is a nutritional compound that provides building blocks your body already uses, but in a combined form that produces more healing-relevant metabolites than either component alone. Human pharmacology studies have confirmed that the combined salt outperforms equimolar doses of its individual components on plasma arginine, insulin, growth hormone, and glutamine levels.
When OKG is absorbed, its two halves interact to saturate a key enzyme (ornithine aminotransferase), which redirects metabolism toward four distinct biosynthetic pathways simultaneously. This metabolic synergy — demonstrated in both animal studies and human pharmacology — is what makes OKG distinctive among nutritional supplements. Where arginine supplements feed one pathway, and glutamine supplements feed another, OKG feeds all four from a single substrate.
How OKG Works: Four Healing Pathways
Collagen Synthesis
Ornithine is converted to proline — accounting for roughly 23% of collagen’s amino acid composition. Simultaneously, the AKG moiety serves as the essential cofactor for prolyl-4-hydroxylase, the enzyme that post-translationally modifies proline residues in collagen. Without adequate AKG, collagen cannot form stable triple-helical structure. Both components are required simultaneously for functional collagen production.
Immune Defence via Glutamine
Ornithine is metabolised to glutamine — the primary fuel for lymphocytes, macrophages, and enterocytes. During catabolic stress, glutamine becomes conditionally essential and tissue concentrations fall. OKG dose-dependently restores tissue glutamine concentrations in endotoxaemic and burn-injured models, supporting immune cell function and gut barrier integrity at the time the body needs it most.
Blood Vessel Growth via Arginine & Nitric Oxide
Ornithine enters the urea cycle to produce citrulline and ultimately arginine — the sole substrate for nitric oxide synthase (NOS). Nitric oxide drives vasodilation, angiogenesis, and macrophage bactericidal activity in the wound site. By supplying ornithine directly, OKG bypasses arginase competition at the wound, where immune cells would otherwise consume arginine before it can reach NOS. This is a mechanistic advantage over direct arginine supplementation.
Cell Proliferation via Polyamines
Ornithine is decarboxylated by ornithine decarboxylase (ODC) to putrescine, the precursor to spermidine and spermine — the polyamine cascade essential for DNA replication and cell proliferation during the wound’s proliferative phase. Animal studies have confirmed elevated tissue polyamine levels in OKG-supplemented subjects following trauma, supporting the fibroblast and epithelial cell proliferation that physically closes wounds.
What the Clinical Research Shows
OKG has been studied in clinical trials since the 1980s. Three landmark RCTs form the core of the evidence base, covering three distinct patient populations: elderly pressure ulcer patients, elderly convalescents, and severely burned patients. Across all three, OKG demonstrated statistically significant improvements in primary healing and recovery endpoints. The evidence has been reviewed by the Cochrane Collaboration (both the burn immunonutrition review by Tan et al. 2014 and the pressure ulcer nutrition review by Langer et al. 2024), which include OKG among interventions with positive evidence.
In the most methodologically rigorous OKG trial, Meaume and colleagues randomised 160 elderly patients (>60 years) with Stage II/III heel pressure ulcers to OKG 10 g/day or placebo for six weeks, in a multicentre, double-blind, placebo-controlled design. The primary endpoint — wound closure rate — showed a statistically significant difference: −0.07 cm²/day in the OKG group versus −0.04 cm²/day in the placebo group (p=0.007), representing a 43% improvement. Thirty serious adverse events were recorded across both groups; none were attributed to OKG treatment.
This is the kind of result that earns clinical nutritionists’ attention: a simple oral supplement producing a measurable, meaningful improvement in a notoriously difficult-to-heal wound type, in a rigorous multicentre trial.
RCT — n=160 elderly patients
RCT — n=194 elderly convalescents
RCT — severe burn patients
Clinical studies — post-surgical
Human pharmacology
Animal models — immune function
Who Benefits Most — and Where the Evidence Is Still Building
The evidence is clearest for elderly patients with pressure ulcers and for severely burned patients receiving enteral nutrition. These are populations where the catabolic demand is extreme, the healing timelines are long, and standard nutritional support alone leaves measurable gaps. The Brocker 1994 trial is particularly notable: a 37% reduction in total care costs from a 10 g/day oral supplement is a health-economic argument that clinical nutrition teams take seriously.
For post-surgical patients, the mechanistic rationale is strong and the older clinical data (Wernerman 1987, 1989) are supportive, but modern RCT evidence is lacking. For athletes or younger adults recovering from musculoskeletal injuries — tendon tears, ligament repairs, stress fractures — the AKG moiety’s role as a prolyl hydroxylase cofactor makes OKG biochemically compelling, but human trials in this population have not yet been conducted. Animal data for tendon-to-bone healing (Wei 2026) and bone mineralisation (Tatara 2006) are encouraging, but preclinical evidence is not a substitute for clinical proof.
OKG is not a replacement for wound care, physiotherapy, or standard clinical nutrition protocols. It is a nutritional substrate that provides the raw materials the body needs to build collagen, fuel immune cells, grow blood vessels, and proliferate new tissue — processes that are rate-limited by amino acid availability in the post-injury state. The evidence suggests it does this more effectively than either of its individual components alone, and from a broader metabolic starting point than single-pathway amino acid supplements.
The Evidence-Based Protocol
| Parameter | What Studies Used |
|---|---|
| Dose | 10 g/day orally for elderly patients and pressure ulcer healing. 20–30 g/day enterally for severe burns and post-surgical patients. No dose-ranging RCTs have been conducted to define an optimal dose. |
| Form | Oral supplement (powder or dissolved form) for ambulatory patients; enteral administration for severely ill patients. The combined salt — not separate ornithine and AKG — is required for metabolic synergy. |
| Duration | 6 weeks (pressure ulcer trial, Meaume 2009); 2 months (convalescent trial, Brocker 1994). Effects persisted 2 months after cessation in the Brocker trial, suggesting structural nutritional improvements rather than transient effects. |
| Combine with | Adequate dietary protein, standard wound care protocols, physiotherapy where appropriate. OKG’s mechanism complements direct arginine/citrulline supplementation (see companion Rejuvenate research), though the combination has not been tested in clinical trials. |
| Safety | Well tolerated at 10–30 g/day across elderly, burn, surgical, paediatric TPN, and HIV patient populations over 40+ years of clinical use. No treatment-related serious adverse events in controlled trials. Mild gastrointestinal effects (nausea, bloating) are reported anecdotally at higher doses. |
What the Research Doesn’t Yet Tell Us
The OKG evidence base has real limitations that deserve honest acknowledgement. The three landmark RCTs date from 1994, 2000, and 2009 — and no large, independent, multicentre replication has been conducted in the past 15 years. The clinical literature is dominated by a single research group centred around Luc Cynober at Paris Descartes University; while this group has produced high-quality work, the absence of independent replication introduces potential systematic bias. The total number of patients enrolled in controlled clinical trials is approximately 500 — enough to detect meaningful effects, but insufficient to detect rare adverse events or perform subgroup analyses.
For musculoskeletal healing — tendons, ligaments, bones, muscle strains — the evidence remains preclinical. The AKG moiety has shown promise in animal models, and the biochemistry (AKG as a cofactor for prolyl hydroxylase) is well-established, but no human RCT has tested OKG specifically for these indications. The most important unmet research need is a large (n≥300), multicentre, double-blind RCT replicating and extending the Meaume 2009 pressure ulcer findings — and pilot studies in orthopaedic surgical populations would begin to address the musculoskeletal gap.
Explore the Full Research
- 📄 Clinical Evidence One-Pager (PDF) — concise summary for clinicians and coaches
- 📋 Full Research Paper (PDF) — complete literature synthesis with evidence tables and grading
- 🔗 Full Reference List — all 54 cited sources in Vancouver format
Want the Full Clinical Evidence?
Download our Clinical Evidence One-Pager for a concise summary of the OKG research — evidence tables, mechanism overview, and dosing context in a single printable document.
Download the Clinical Evidence One-PagerKey References
- Meaume S, et al. Efficacy and safety of ornithine alpha-ketoglutarate in heel pressure ulcers in elderly patients: results of a randomized controlled trial. J Nutr Health Aging. 2009;13(7):623–630. PMID: 19621198
- Brocker P, et al. A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects. Age Ageing. 1994;23(4):303–306. PMID: 7976777
- Coudray-Lucas C, et al. Ornithine alpha-ketoglutarate improves wound healing in severe burn patients: a prospective randomized double-blind trial versus isonitrogenous controls. Crit Care Med. 2000;28(6):1772–1776. PMID: 10890617
- Cynober L. Ornithine alpha-ketoglutarate as a potent precursor of arginine and nitric oxide: a new job for an old friend. J Nutr. 2004;134(10 Suppl):2858S–2862S. PMID: 15465801
- Wernerman J, et al. Ornithine-alpha-ketoglutarate improves skeletal muscle protein synthesis as assessed by ribosome analysis and nitrogen use after surgery. Ann Surg. 1987;206(5):674–678. PMID: 3118827
- Cynober L, et al. Action of ornithine alpha-ketoglutarate, ornithine hydrochloride, and calcium alpha-ketoglutarate on plasma amino acid and hormonal patterns in healthy subjects. J Am Coll Nutr. 1990;9(1):2–12. PMID: 2407764